MedPath

Efficacy of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Not Applicable
Conditions
Hepatocellular Carcinoma
Registration Number
JPRN-UMIN000042750
Lead Sponsor
Gifu university first Dept of internalmedicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

1Untreated or incompletely treated esophageal or gastric varices.2With bleeding or high risk of bleeding.3Thromboembolic event.4Wounded.5Brain metastasis.6Uncontrolled Hypertension. 7Uncontrolled Ascites. 8History of autoimmune disease. 9Pulmonary fibrosis. 10Tuberculosis. 11Severe Hart failure. 12Long QT Syndrome. 13infection within 4weeks. 14Vaccination within 4weeks. 15Pregnant. 16Allergic. 17Un suitable Patient.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath